No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
CRDF241220P3500
- 0.10
- -0.25-71.43%
15min DelayClose Dec 13 16:00 ET
0.28High0.10Low
0.18Open0.35Pre Close727 Volume366 Open Interest3.50Strike Price10.22KTurnover179.31%IV13.27%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.2731Delta0.3616Gamma22.40Leverage Ratio-0.0251Theta-0.0002Rho-6.12Eff Leverage0.0017Vega
Intraday
- 5D
- Daily
News
Cardiff Oncology Is Maintained at Overweight by Piper Sandler
Cardiff Oncology Analyst Ratings
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Raises Target Price to $10
TD Cowen Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Cardiff Oncology Director Gary Pace Buys $940,199 in Stock
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study